Moxifloxacin in COPD: pharmacokinetics and penetration into bronchial secretions in ward and ICU patients.
Antimicrob Agents Chemother. 2019 Jan 14;:
Authors: Sionidou M, Manika K, Pitsiou G, Kontou P, Chatzika K, Zarogoulidis P, Kioumis I
This study aims to evaluate moxifloxacin's (MXF's) pharmacokinetic profile in serum and sputum/bronchial secretions of 22 patients, with acute exacerbation of COPD (AECOPD), hospitalized in ward and ICU. The data showed that ICU patients had lower concentration in secretions (p=0.01).Thought, no other statistically significant differences were observed in pharmacokinetic parameters and penetration in secretions between less and critically ill. MXF showed a favorable pharmacokinetic profile and the pharmacodynamic targets for common pathogens for AECOPD were achieved.
PMID: 30642928 [PubMed - as supplied by publisher]